2906 studies found for:    non-Hodgkin's lymphoma
Show Display Options
Download search resultsDownload the search results for:
non-Hodgkin's lymphoma (2906 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: ABT-199;   Drug: Bendamustine;   Drug: Rituximab
2 Completed Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Conditions: Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: bendamustine hydrochloride
3 Completed Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine I 131 Tositumomab
4 Completed SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: bendamustine and rituximab
5 Completed A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Everolmus
6 Completed
Has Results
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Oxaliplatin
7 Withdrawn A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
Condition: Relapsed/Refractory Non-Hodgkin's Lymphoma
Intervention: Drug: [14C]ABT-199 (GDC-0199)
8 Active, not recruiting Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Dasatinib
9 Terminated Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin’s Lymphoma and Solid Tumors
Conditions: Non-Hodgkin's Lymphoma,;   Solid Tumors
Intervention: Drug: PPI-2458
10 Completed Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy
Conditions: Chemotherapy-Induced Nausea and Vomiting;   Non Hodgkin's Lymphoma
Intervention: Drug: Palonosetron
11 Completed
Has Results
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Conditions: Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Interventions: Drug: TG-0054 (2.24 mg/kg);   Drug: TG-0054 (3.14 mg/kg)
12 Recruiting Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Interventions: Biological: Antigen-Escalation Stage;   Biological: Dose-Escalation Study of T Cells
13 Recruiting Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
Condition: Non Hodgkin's Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide
14 Completed Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Zevalin-BuCyE
15 Recruiting Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Condition: Indolent Non-Hodgkin's Lymphoma
Interventions: Biological: Arm A: Rituximab;   Biological: Arm B: GA101
16 Completed Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Indolent Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Fludarabine;   Drug: Everolimus;   Drug: Bortezomib;   Drug: Chlorambucil;   Drug: Lenalidomide
17 Active, not recruiting PEARL Study: Improvement of Non-Hodgkin's Lymphoma Care
Condition: Non-Hodgkin Lymphoma
Interventions: Other: Implementation tools;   Other: Standard intervention
18 Completed Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention:
19 Recruiting Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Intervention: Drug: LBH589
20 Withdrawn Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Vorinostat in combination with Bortezomib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years